← Leaderboards
Manijeh N Goldberg
Privo Technologies, Llc
$11,254,955
Attributed
$17,820,376
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,773,009 · 5
FDA$1,047,367 · 1
By mechanism
R44$16,552,334 · 4
R01$1,047,367 · 1
R43$220,675 · 1
Top collaborators
- Donna Keith11 shared
- Jesse Hall3 shared
- Marcus Webb2 shared
- Kuanju Chen1 shared
Most similar at Privo Technologies, Llc
Same institution · by research overlap
- Donna Keith$4,266,547
- Jesse Hall$523,684
- Marcus Webb$1,664,854
- Kuanju Chen$110,338
Others in their field
Top investigators on “Malignant Mouth Neoplasm”
- David Heimbrook · Leidos Biomedical Research, Inc.$32,281,639
- David T Wong · University Of California Los Angeles$16,474,329
- Brian L Schmidt · New York University$11,360,127
- Larry Arthur$10,367,759
- Nisha J D'silva · University Of Michigan At Ann Arbor$10,276,806
- Susan R Mallery · Ohio State University$9,844,599
Research focus
Malignant Mouth NeoplasmCisplatinToxic EffectPharmaceutical PreparationsFundingNanoengineeringTumorClinical TrialsEnsureChemotherapySurvival RateIntravenousFoundationsHourDesignCessation Of LifeMalignant NeoplasmsNanotechnologySafetyDocumentationNanoparticleAnimalsIncidencePlatinum
Grant awards (23)
Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)$1,245,681
R44 · FY2025 · CA · contact PI
Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)$2,084,026
R44 · FY2024 · CA · contact PI
Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings$1,012,303
R44 · FY2024 · CA · contact PI
Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings$987,292
R44 · FY2023 · CA · contact PI
Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy$984,664
R44 · FY2023 · DE · contact PI
Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy$779,005
R44 · FY2022 · DE · contact PI
Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings$401,107
R44 · FY2022 · CA · contact PI
Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy$1,183,038
R44 · FY2021 · DE · contact PI
Highly focused loco-regional chemotherapy for oral cancer - IND 132234 - October 01 2017$99,660
R01 · FY2021 · FD · contact PI
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer$1,000,447
R44 · FY2020 · CA · contact PI
Highly focused loco-regional chemotherapy for oral cancer - IND 132234 - October 01 2017$498,400
R01 · FY2020 · FD · contact PI
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer$1,083,847
R44 · FY2019 · CA · contact PI
Highly focused loco-regional chemotherapy for oral cancer - IND 132234 - October 01 2017$449,307
R01 · FY2019 · FD · contact PI
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer$98,000
R44 · FY2019 · CA · contact PI
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer$4,318
R44 · FY2019 · CA · contact PI
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer$999,072
R44 · FY2018 · CA · contact PI
FAST TRACK: IND Enabling Studies for Oral Cancer$1,170,342
R44 · FY2017 · CA · contact PI
Customized Nanotechnology Based Treatment of Oral Cancer$999,997
R44 · FY2017 · DE · contact PI
Customized Nanotechnology Based Treatment of Oral Cancer$999,997
R44 · FY2016 · DE · contact PI
FAST TRACK: IND Enabling Studies for Oral Cancer$960,707
R44 · FY2016 · CA · contact PI
Customized Nanotechnology Based Treatment of Oral Cancer$265,000
R44 · FY2016 · DE · contact PI
FAST TRACK: IND Enabling Studies for Oral Cancer$293,491
R44 · FY2015 · CA · contact PI
Customized nanotechnology based treatment of Oral Cancer$220,675
R43 · FY2014 · DE · contact PI